# Erratum to: Antiplatelet therapy with CABG: chaos in the Netherlands 

F. W. A. Verheugt ${ }^{1}$

Published online: 9 August 2017
© The Author(s) 2017. This article is an open access publication.

## Erratum to:

Neth Heart J 2017
DOI 10.1007/s12471-017-1022-z
In the PDF version of the article, Tab. 1 was incorrectly displayed. The corrected version is shown below.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Table 1 Recommendation with level of evidence of timing and duration of antiplatelet therapy peri-CABG

|  |  |  | CABG Indication |  |
| :--- | :--- | :--- | :--- | :--- |
| Timing | Agent | Stable CAD <br> without stent(s) | Stable CAD <br> with recent stent(s) | ACS <br> with or without stent(s) |
| Preoperative | Aspirin | Continue (IA) | Continue (IA) | Continue (IA) |
|  | P2Y12 | n.a. | Stop 5-7days (IIA) | Stop 5-7 days (IIA) |
| Postoperative | Aspirin | Lifelong (IA) | Lifelong (IA) | Lifyelong (IA) |
|  | P2Y12 | n.a. | Day 1 restart (IIA) $^{\text {c }}$ | Day 1 restart (IIB) ${ }^{\text {d }}$ |

n.a. not applicable
${ }^{\text {a }}$ Unless expected periperative high bleeding risk
${ }^{\mathrm{b}}$ Unless continued clinical instability
${ }^{\mathrm{c}}$ Duration depending on stent type and patient charcteristics
${ }^{\mathrm{d}}$ Duration at least 1 year after index ACS

[^0] 10.1007/s12471-017-1022-z.

[^1]
[^0]:    The online version of the original article can be found under doi:

[^1]:    $\boxtimes$ F. W. A. Verheugt
    f.w.a.verheugt@olvg.nl

    1 Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

